Browsing Radiotherapy and Imaging by author "Bliss, Judith"
Now showing items 1-15 of 15
-
5-fraction radiotherapy for breast cancer: FAST Forward to implementation.
Somaiah, N; Brunt, AM; Haviland, JS; Kirby, AM; Wheatley, D; et al. (Elsevier, 2023-05-19) -
Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.
Brunt, AM; Wheatley, D; Yarnold, J; Somaiah, N; Kelly, S; et al. (ELSEVIER IRELAND LTD, 2016-07-15)BACKGROUND AND PURPOSE: FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin ... -
Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer?
Bhattacharya, IS; Kirby, AM; Bliss, JM; Coles, CE (ELSEVIER SCIENCE LONDON, 2018-03-01)Adjuvant radiotherapy after breast-conserving surgery has been an important component of the standard of care for early breast cancer. Improvements in breast cancer care have resulted in a substantial reduction in local ... -
Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial.
Bhattacharya, IS; Haviland, JS; Hopwood, P; Coles, CE; Yarnold, JR; et al. (ELSEVIER IRELAND LTD, 2019-05)BACKGROUND: In an era of low local relapse rates after adjuvant breast radiotherapy, risks of late normal-tissue effects (NTE) need to be balanced against risk of relapse. NTE are assessed using patient-reported outcome ... -
FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.
Wilkins, A; Chauhan, R; Rust, A; Pearson, A; Daley, F; et al. (SPRINGER, 2018-08-01)BACKGROUND: Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline ... -
Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation.
Brunt, AM; Haviland, JS; Kirby, AM; Somaiah, N; Wheatley, DA; et al. (ELSEVIER SCIENCE LONDON, 2023-05-19)INTRODUCTION: The phase 3 FAST-Forward trial reported outcomes for 26 and 27 Gy schedules delivered in 5 fractions over 1 week versus 40 Gy in 15 fractions over 3 weeks in 4000 patients. We discuss concerns raised by the ... -
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
Haviland, J; Sydenham, M; Hopwood, P; Kirby, A; Somaiah, N; et al. -
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Murray Brunt, A; Haviland, JS; Wheatley, DA; Sydenham, MA; Alhasso, A; et al. (ELSEVIER SCIENCE INC, 2020-05-23)BACKGROUND: We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard ... -
Is breast seroma after tumour resection associated with patient-reported breast appearance change following radiotherapy? Results from the IMPORT HIGH (CRUK/06/003) trial.
Bhattacharya, IS; Haviland, JS; Perotti, C; Eaton, D; Gulliford, S; et al. (ELSEVIER IRELAND LTD, 2019-07)BACKGROUND: Seroma describes a collection of serous fluid within a cavity, occurring following surgery. Seroma is associated with normal tissue effects (NTE) following breast radiotherapy, as reported by clinicians and on ... -
Partial breast radiotherapy after breast conservation surgery for early breast cancer: 5-year outcomes from the IMPORT LOW (CRUK/06/003) phase III randomised controlled trial
Coles, C; Griffin, C; Kirby, A; Titley, J; Agrawal, R; et al. (2017-05-15) -
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Coles, CE; Griffin, CL; Kirby, AM; Titley, J; Agrawal, RK; et al. (ELSEVIER SCIENCE INC, 2017-09-09)BACKGROUND: Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that ... -
Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial.
Bhattacharya, IS; Haviland, JS; Kirby, AM; Kirwan, CC; Hopwood, P; et al. (2019-02)Purpose IMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy versus whole-breast radiotherapy for local relapse and similar or reduced toxicity at 5 years. Comprehensive patient-reported ... -
Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial.
Bhattacharya, IS; Haviland, JS; Kirby, AM; Kirwan, CC; Hopwood, P; et al. (AMER SOC CLINICAL ONCOLOGY, 2019-02-01)PURPOSE: IMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy versus whole-breast radiotherapy for local relapse and similar or reduced toxicity at 5 years. Comprehensive patient-reported ... -
Proton Beam Therapy in Breast Cancer Patients: The UK PARABLE Trial is Recruiting.
Kirby, AM; Haviland, JS; Mackenzie, M; Fleming, H; Anandadas, C; et al. (ELSEVIER SCIENCE LONDON, 2023-06-01) -
Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial.
Hayes, AJ; Maynard, L; Coombes, G; Newton-Bishop, J; Timmons, M; et al. (ELSEVIER SCIENCE INC, 2016-02-01)BACKGROUND: The necessary margin of excision for cutaneous melanomas greater than 2 mm in thickness is controversial. At a median follow-up of 5 years, findings from our previously published randomised trial of narrow (1 ...